News
The genome incorporation mechanism for LINE-1, the only autonomously active retrotransposon in humans, leverages the cell ...
A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback